Article Listing - Sanofi-Synthelabo sales climb 15.4%, driven by three blockbusters

FERMENTA INTO LOSS

6 April 1992

Swedish drugmaker Fermenta reported a 1.23 billion kroner ($203.4 million) loss for 1991, compared with a loss of 599 million...

STOCK MARKET COMMENTARY: NEW YORK

6 April 1992

NEW YORK: share prices moved up and down during the reporting week, first with lower car sales pushing the Dow...

US MEDICAID REBATES AND "BEST PRICES"

6 April 1992

Eliminating the "best price" provision from the US Medicaid rebate formula for the top 100 single-source and innovator multiple-source drugs...

US FDA USER FEES: "THE TIME HAS COME"

6 April 1992

People in the US Food and Drug Administration-regulated industries now recognize that the time has arrived for user fees to...

ICN HUBBER GROUP IN SPAIN

6 April 1992

The ICN Hubber Group is investing 1.7 billion pesetas ($2.2 million) in a new pharmaceutical plant near Barcelona in Spain....

NEW PRES AT PROCORDIA

6 April 1992

Jan Ekberg has been named as president and chief executive at Procordia, in succession to Soren Gyll who has become...

PHARMA COs TOP R&D SPEND IN JAPAN

6 April 1992

Of 16 Japanese companies planning to spend over 10% of their sales on R&D in 1992, nine are pharmaceutical companies,...

AUSTRALIAN LAUNCH OF ROCHE'S AURORIX

6 April 1992

Hoffmann-La Roche's reversible inhibitor of monoamine oxidase type A, Aurorix (moclobemide) has now been launched in Australia. The novel antidepressant...

AMA REPORT ON CONTRACEPTIVES

6 April 1992

The outcome of a report from the American Medical Association's Board of Trustees concludes that long-acting contraceptives may be medically...

ICN-GALENIKA "HEALTHY SHARES"

6 April 1992

Yugoslavia's Tanjug news agency reports that Milan Panic, head of ICN-Galenika and founder of US-based ICN Pharmaceuticals, is saying the...

Showing 94721-94730 of 95576 articles